Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 1/2019

01-01-2019 | Meeting Report

Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017

Authors: Michele Maio, Maria Fortunata Lofiego, Carolina Fazio, Sara Cannito, Carla Chiarucci, Gianluca Giacobini, Monica Valente, Patrizia Tunici, Alessia Covre, Vincenzo Russo

Published in: Cancer Immunology, Immunotherapy | Issue 1/2019

Login to get access

Excerpt

The XV annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) took place in Siena, Tuscany, on October 5–7, 2017. International leading scientists from academic institutions and pharmaceutical companies presented updates on new research achievements in cancer bio-immunotherapy. The meeting aimed to build a close connection between clinical and pre-clinical research. Many topics were discussed during the meeting, such as (a) tumor microenvironment; (b) epigenetics, immune cells and cancer; (c) commensal microorganisms, food, immune cells and cancer; (d) immune agonists and antagonists; (e) active and adoptive immunotherapy; (f) prospective NIBIT and NIBIT Foundation collaborations. There follows a brief summary of the topics discussed in the meeting. …
Metadata
Title
Fifteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 5–7, 2017
Authors
Michele Maio
Maria Fortunata Lofiego
Carolina Fazio
Sara Cannito
Carla Chiarucci
Gianluca Giacobini
Monica Valente
Patrizia Tunici
Alessia Covre
Vincenzo Russo
Publication date
01-01-2019
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 1/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-018-2222-0

Other articles of this Issue 1/2019

Cancer Immunology, Immunotherapy 1/2019 Go to the issue

Opinion Paper

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

Original Article

Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma

Original Article

An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells

Original Article

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Original Article

Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics

Original Article

Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits